These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10848363)

  • 1. LVADs--a new era in patient care.
    Poirier VL
    J Cardiovasc Manag; 2000; 11(2):26-34. PubMed ID: 10848363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic relief: left ventricular assist devices versus resynchronization therapy.
    Delgado RM; Radovancevic B
    Heart Fail Clin; 2007 Jul; 3(3):259-65. PubMed ID: 17723934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of left ventricular-assist devices in end-stage heart failure.
    Hutchinson J; Scott DA; Clegg AJ; Loveman E; Royle P; Bryant J; Colquitt JL
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):175-85. PubMed ID: 18248272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.
    Lietz K; Long JW; Kfoury AG; Slaughter MS; Silver MA; Milano CA; Rogers JG; Naka Y; Mancini D; Miller LW
    Circulation; 2007 Jul; 116(5):497-505. PubMed ID: 17638928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New hope for failing hearts.
    Gorman C
    Time; 2001 Nov; 158(23):97. PubMed ID: 11817278
    [No Abstract]   [Full Text] [Related]  

  • 6. Hospital costs for left ventricular assist devices for destination therapy: lower costs for implantation in the post-REMATCH era.
    Miller LW; Nelson KE; Bostic RR; Tong K; Slaughter MS; Long JW
    J Heart Lung Transplant; 2006 Jul; 25(7):778-84. PubMed ID: 16818120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the MicroMed DeBakey VAD for the treatment of end-stage heart failure.
    DeBakey ME; Teitel ER
    Expert Rev Med Devices; 2005 Mar; 2(2):137-40. PubMed ID: 16293049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Special report: cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure.
    Technol Eval Cent Assess Program Exec Summ; 2004 Apr; 19(2):1. PubMed ID: 15314825
    [No Abstract]   [Full Text] [Related]  

  • 9. Heart transplant and left ventricular assist device costs.
    Digiorgi PL; Reel MS; Thornton B; Burton E; Naka Y; Oz MC
    J Heart Lung Transplant; 2005 Feb; 24(2):200-4. PubMed ID: 15701438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).
    Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D;
    Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AbioCor totally implantable artificial heart. How will it impact hospitals?
    Health Devices; 2002 Sep; 31(9):332-41. PubMed ID: 12400223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The next treatment option: using ventricular assist devices for heart failure.
    Stahovich M; Chillcott S; Dembitsky WP
    Crit Care Nurs Q; 2007; 30(4):337-46. PubMed ID: 17873570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes are similar in pulsatile and nonpulsatile left ventricular assist device recipients.
    Feller ED; Sorensen EN; Haddad M; Pierson RN; Johnson FL; Brown JM; Griffith BP
    Ann Thorac Surg; 2007 Mar; 83(3):1082-8. PubMed ID: 17307463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Economic aspects of implementation of the mechanical heart, "HeartMate"].
    Kolbye A; Sander Jensen KM; Aldershvile J; Hansen PB; Kjersem AM; Nielsen KS; Olsen PS; Rasmussen B; Vogelsang G
    Ugeskr Laeger; 2000 Jun; 162(26):3722-5. PubMed ID: 10925632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy?
    Levy WC; Mozaffarian D; Linker DT; Farrar DJ; Miller LW;
    J Heart Lung Transplant; 2009 Mar; 28(3):231-6. PubMed ID: 19285613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does continuous flow left ventricular assist device technology have a positive impact on outcome pretransplant and posttransplant?
    Klotz S; Stypmann J; Welp H; Schmid C; Drees G; Rukosujew A; Scheld HH
    Ann Thorac Surg; 2006 Nov; 82(5):1774-8. PubMed ID: 17062246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanical circulatory support systems--a review.
    Mihaylov D; Verkerke GJ; Rakhorst G
    Technol Health Care; 2000; 8(5):251-66. PubMed ID: 11204171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventricular assist device therapy.
    Sayer G; Naka Y; Jorde UP
    Cardiovasc Ther; 2009; 27(2):140-50. PubMed ID: 19426251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving outcomes with long-term "destination" therapy using left ventricular assist devices.
    Long JW; Healy AH; Rasmusson BY; Cowley CG; Nelson KE; Kfoury AG; Clayson SE; Reid BB; Moore SA; Blank DU; Renlund DG
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1353-60; discussion 1360-1. PubMed ID: 18544385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac recovery during mechanical assist device support.
    Maybaum S; Kamalakannan G; Murthy S
    Semin Thorac Cardiovasc Surg; 2008; 20(3):234-46. PubMed ID: 19038734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.